Lexicon Pharmaceuticals — Third Quarter 2026 Earnings Summary

Lexicon Pharmaceuticals reported third-quarter 2026 total revenues of $11.3 million, driven by $10.0 million in development milestone payments from Novo and $1.2 million in net sales of INPEFA. The company completed enrollment in the Phase 3 SONATA-HCM study with 542 patients and expects top-line data in the first quarter of 2027, while positive safety data from the STENO1 study supports a planned ZYNQUISTA NDA resubmission in the same period. Lexicon's cash and investments increased to $183.2 million as of September 30, 2026, following a $96.2 million equity offering in February. The company also earned a third $10 million milestone payment from Novo for LX9851, bringing total potential milestone earnings to $75 million under their collaboration agreement.